Ipsen and Servier's hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cance
Roche's Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous formulation, after the new version matched the original intravenous formulat
Ipsen has joined the ranks of companies working on T cell receptor (TCR) therapies for cancer, paying $45 million upfront for rights to early-stage candidates developed by US biotech Mareng
AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer, after an interim analysis suggested it was unlikely to show a be